1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Valuation
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
VVVV
Sector
Health Care
Subsector
Health Care Equipment & Supplies
Offer Range
—
Shares Offered
—
—
Implied Upside vs Midpoint
Description
Our Vision and Mission We were founded in Switzerland by Dr. Haley Abivardi and Dr. Goly Abivardi—internationally renowned dentists and serial entrepreneurs—with a vision to improve overall health globally by defining and establishing a new category in oral health. Our mission is to create a world where cavity treatment is pain-free, regenerative and accessible to all. We believe, drawing on our industry experience, market understanding and extensive clinical evidence, that we have created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth. Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options. Our Curodont® platform includes our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets. Our flagship Curodont® products are based on proprietary, peptide-containing formulations that complement the patient’s natural biology to help it stop the progression of early-stage cavities, preserve natural tooth structure and repair damaged enamel in early-stage cavities, establishing a new drill-free restorative category that we believe aligns clinical and economic incentives for patients, dental practitioners and payors. We have accumulated a robust body of scientific evidence over the last 25 years that demonstrates the clinical performance, tolerability and observed outcomes of Curodont®’s underlying technology. Following our U.S. commercial launch in January 2024, we have achieved rapid clinical adoption, and estimate that our products have treated over three-and-a-half million teeth as of June 30, 2026, with our flagship Curodont® products having been sold to over 20,000 of the approximately 110,000 general dental practices in the United States. In the year ended December 31, 2025, and the last six months ended June 30, 2026, we have achieved $30.2 million and $28.6 million in net revenue, representing a year-over-year growth rate of 148.5% and 214.2%, respectively, and gross profit of $22.4 million and $24.7 million, representing a gross margin of 74.2% and 86.4%, respectively. Curodont® Repair Fluoride Plus is distributed in the United States, where it is regulated as an over-the-counter (“OTC”) drug product by the U.S. Food and Drug Administration (the “FDA”) on the basis of its sodium fluoride content. Because Curodont® Repair Fluoride Plus is regulated as an OTC drug product in the United States, the FDA has not made any determination regarding its safety or efficacy. Tooth decay affects approximately 2.5 billion people globally, according to the World Health Organization. Based on analyses performed by the National Center for Health Statistics and the CDC, approximately 63-65% of the general population in the United States visit the dentist annually. Among children, annual dental visitation rates are even higher, ranging from 80% to 90%. Based on our survey of existing clinical and academic literature and data from our partners, we estimate that approximately 75-85% of the U.S. population has at least one early-stage cavity and such affected patients have, on average, four to five early-stage cavities. Taken together, we estimate this translates to an estimated 1 billion early-stage cavities in the United States alone, representing a TAM for Curodont® of approximately $29 billion. This figure represents the total estimated number of early-stage cavities across the entire U.S. population, including those that we estimate to be undiagnosed among the approximately 35-37% of the population that does not currently visit a dentist. We estimate that our SAM, which represents the subset of addressable early-stage cavities found among patients who visit a dentist at least once per year and whose cavities are currently identified and clinically managed, comprises at least 450 million treatable early-stage cavities, representing a market opportunity of at least $13 billion. Further, we estimate that the increasing adoption of AI-powered cavity detection platforms could expand our market opportunity by more than 30%, driven by both increased identification of early-stage cavities—approximately 30% to 40% higher identification than unaided clinical assessment, based on data collected by Overjet and VideaHealth—and higher patient treatment acceptance through AI-enabled workflows, according to data from our partners. Assuming a 100% detection rate of cavities, we estimate that our SAM would be at least $20 billion. We are disrupting a multi-decade period of technological stagnation in the dental market. Since the introduction of the dental drill in the 1950s, the “watch-and-wait” and “drill-and-fill” treatment options for cavity management have remained fundamentally unchanged, creating a critical therapeutic gap between preventative-only and invasive intervention. In particular, at ICDAS 1 and 2, which refer to early-stage, non-cavitated lesions under the International Caries Detection and Assessment System (the “ICDAS”), existing treatment options are generally limited to “watch-and-wait” and “drill-and-fill” approaches, which we believe do not adequately address patient needs, resulting in a treatment gap. Our platform closes this gap for such early-stage cavities by providing clinicians with a non-invasive restorative alternative, which we believe can become a new standard of care. Existing professional treatment options for early-stage cavities generally consist of preventative interventions, which are designed primarily to reduce the risk of future decay rather than reverse an established lesion, or invasive procedures, which are appropriate only after more extensive cavitation has occurred. Fluoride varnish (“FV”), the most widely used professional preventive measure for cavity management, is generally intended to help prevent future cavity formation rather than treat existing disease. As a result, we believe there are currently no commercially available products that directly compete with Curodont® in providing a clinically validated, non-invasive restorative treatment for early-stage cavities. As our products are intended for use at ICDAS 1 and 2, our products may not be suitable for more advanced stages of tooth decay, at which point conventional restorative interventions may be required. Our flagship Curodont® products utilize proprietary, peptide-containing formulations that initiate a biomimetic process of mineral crystal formation within early-stage cavities–a process that mimics the mechanisms underpinning natural enamel formation. We believe Curodont® can transform the patient and dental practitioner experience and address many of the limitations of conventional treatments by providing the following key benefits: Patient Benefits: • Patient-friendly: needle-free, drill-free and pain-free • Non-invasive: natural tooth structure is preserved • Clinically validated: extensive clinical evidence supporting performance and tolerability • Efficient: up to five-minute treatment duration and single visit procedure • Affordable: comparable treatment cost to small, single-surface “drill-and-fill” procedure, with the potential to minimize future costs associated with increasingly invasive procedures Practice and Dental Practitioner Benefits: • New, billable treatment option: alternative to the current treatment options for early-stage cavities (“watch-and-wait” and “drill-and-fill”) • Efficient: up to five-minute treatment duration and single-visit procedure, reducing “no show” follow-up appointments • Economical: quicker treatment that allows higher revenue per hour of chair time than conventional treatment options • Simple-to-use technology: can be performed by a hygienist and requires no extensive or specialized training beyond standard clinical competencies • Patient compliance: supports greater patient retention and visit frequency We have a rigorous, multi-modal evidence compendium that demonstrates the clinical performance and tolerability and economic benefits of Curodont®. This evidence base encompasses randomized controlled trials, systematic reviews, meta-analyses and long-term real-world cohort analyses across both pediatric and adult populations that assess clinically relevant endpoints such as cavity regression, lesion size, radiographic regression and lesion activity. Our scientific evidence has been published in more than 250 publications, including in leading peer-reviewed journals such as the Journal of the American Dental Association, the Journal of Dental Research, Scientific Reports and Clinical Oral Investigations. Across this evidence base, Curodont® has been demonstrated to be highly effective in arresting or reversing early-stage cavities, in many cases after only a single application, including at two- to six-year follow-up periods. Our commercial strategy is initially focused on driving adoption of Curodont® in the United States and Europe. We commercialize our flagship Curodont® product in the United States through a hybrid model that leverages both our specialized direct sales force and extensive sales and distribution platform of Henry Schein, Inc. (“Henry Schein”), our exclusive distributor in the United States and the United Kingdom. Our U.S. commercial organization includes key account managers focused on practice acquisition and onboarding, an internal sales team focused on repeat purchasing and clinical education specialists providing onsite training and continuing education. As of June 30, 2026, our team consisted of 64 key account managers, 7 internal sales representatives, 11 clinical education specialists and a 9-person marketing team. Awareness and education remain core pillars of our market development strategy. Although awareness of Curodont® continues to grow, it remains limited, and we are addressing this awareness gap through a dual-pronged approach—institutionalization, with Curodont® currently featured in the curricula of over 50 U.S. and European dental programs, and peer-led advocacy, utilizing a network of key opinion leaders (“KOLs”)—to support clinician education and adoption. We are further expanding our commercial reach by piloting targeted in-office and direct-to-patient marketing to accelerate patient-driven demand. We are also leading a clinical shift among practitioners who are increasingly embracing our philosophy of preserving tooth structure and improving the quality of patients’ lives, whom we refer to as Curodontists®. We are committed to advancing our Curodont® technology platform through continued innovation, with a strategic focus on next-generation peptides, expanded clinical use cases and the application of AI and ML. We are actively investing in research and development programs, including new oral health indications and products across large and underserved categories, such as later-stage cavities and hard- and soft-tissue solutions. We are also strategically evaluating future applications outside of dentistry. --- We were incorporated as a Swiss stock corporation (Aktiengesellschaft; société anonyme) on November 11, 2020, and are registered with the register of commerce of the Canton of Zug (company registration number CHE-304.163.134), having its registered office at Gubelstrasse 24, 6300 Zug, Switzerland. Our telephone number is +41 78 258 4860. Our website is www.vvardis.com. Our main U.S. subsidiary is vVARDIS Inc., a Delaware corporation. Its principal office is located at 99 Wall Street, Suite 1836, New York, New York 10005, and the telephone number at that office is +1 903 738 8333. Our agent for service of process in the United States is vVARDIS Inc.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||